Pentadeca Arginate (PDA)
Also known as PDA, Pentadecapeptide Arginate, BPC-157 Arginate
A newer arginate-salt analog of BPC-157 engineered for greater stability and shelf life. Marketed as a next-generation healing and tissue-repair peptide for tendons, ligaments, gut, and soft tissue.
How it works
Believed to share BPC-157's mechanisms: upregulating growth-factor and VEGF pathways, modulating nitric oxide, and acting on the FAK-paxillin pathway to promote angiogenesis and fibroblast activity. The arginate salt improves molecular stability.
Benefits
- Accelerates soft-tissue, tendon, and ligament healing
- Supports gut-lining repair
- Reduces inflammation
- May improve vascularization (angiogenesis)
- More stable than standard BPC-157
Dosing
250–500 mcg · 1-2x daily
Commonly 250-500 mcg 1-2x/day SubQ, often near the injury site. Protocols mirror BPC-157.
Ranges reflect commonly cited research protocols, not a prescription. Dose with a licensed provider.
Reconstitution
Lyophilized powder reconstituted with BAC water; refrigerate.
Helix’s free reconstitution calculator gives you the exact draw volume → get the app
Common stacks
Reported side effects
- Generally well tolerated
- Injection-site irritation
- Occasional fatigue, nausea, or headache
- Limited long-term human safety data
Who it’s for
Those recovering from soft-tissue injury or seeking gut and recovery support, especially anyone who prefers a more stable BPC-157 form.
Track Pentadeca Arginate (PDA) in Helix
Dose reminders, reconstitution math, vial tracking, and AI guidance — free on iOS.
Download free